CNMD, US2074101013

Argus raises target for CONMED stock to USD 48.00

Published on 10/20/2026 at 18:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 28, 2026 after the close. CONMED stock costs EUR 41.70 on October 20, 2026 at 6:36 p.m. CEST.

Analyst target and reporting date

Argus set a USD 48.00 target for CONMED on October 14, 2026.
CONMED will report third-quarter results on October 28, 2026.
CONMED stock costs EUR 41.70 at Lang & Schwarz on October 20, 2026 at 6:36 p.m. CEST.
Second-quarter revenue was USD 343.49 million in 2026, flat year over year.

CNMD, US2074101013, Illustration mit AI erstellt.

CONMED (ISIN US2074101013) has an Argus price target of USD 48.00 dated October 14, 2026, according to Yahoo Finance. The company is scheduled to report third-quarter results on October 28, 2026. CONMED stock was trading at EUR 41.70 at Lang & Schwarz on October 20, 2026 at 6:36 p.m. CEST.

Argus target sets a higher bar

The USD 48.00 target puts the analyst view above CONMED's USD 46.86 NYSE price at 12:41 p.m. EDT on October 20, 2026. The target is 2.43 percent above that US price, calculated from the two USD values. The target note does not state an earlier target in the fetched report.

CONMED's second-quarter 2026 revenue reached USD 343.49 million, flat year over year and 1.80 percent above analyst expectations, according to Yahoo Finance. Net income was USD 23.10 million, while earnings per share came to USD 0.77 for the quarter.

Stock stays below its yearly high

CONMED's USD 31.44 to USD 53.66 52-week range and USD 1.4 billion market capitalization were available as of October 20, 2026. The US price of USD 46.86 stood 12.66 percent below the 52-week high, leaving the share below its yearly peak despite the latest target.

The company operates in medical devices and supplies for orthopedic, general, gynecological and thoracic surgery. Its scheduled third-quarter release will arrive after the market close on October 28, 2026, with management due to discuss the results at 4:30 p.m. ET, according to CONMED.

What does the next report add?

The October 28 report will test whether quarterly revenue can move beyond the USD 343.49 million level reported for the second quarter. It will also give investors a fresh comparison with the company guidance and the USD 48.00 Argus target.

Price and valuation context

CONMED traded at a trailing price-to-earnings multiple of 25.30 on October 20, 2026. Stryker traded at USD 303.89 with a 31.45 multiple and a USD 116.6 billion market capitalization, while Boston Scientific traded at USD 45.52 with an 18.49 multiple and a USD 66.0 billion market capitalization on the same date.

CONMED stock at Lang & Schwarz

CONMED stock was trading at EUR 41.70 at Lang & Schwarz on October 20, 2026 at 6:36 p.m. CEST. The Xetra close could not be used as a dated comparison in this report, so the article states the euro price without a daily percentage.

The further course of trading is shown by the continuously updated real-time quote of CONMED stock.